SLGL vs GDRX vs HIMS vs DERM vs SKIN

For growth investors, Sol-Gel Technologies Ltd.

(SLGL) is the stronger pick with 68. 0% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). GoodRx Holdings, Inc. (GDRX) offers the better valuation at 34. 2x trailing P/E (9. 4x forward), making it the more compelling value choice. Analysts rate Sol-Gel Technologies Ltd. (SLGL) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, GoodRx Holdings, Inc.

(GDRX) is the cheapest at 34. 2x versus Hims & Hers Health, Inc. at 55. 4x. On forward P/E, GoodRx Holdings, Inc. is actually cheaper at 9. 4x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +173. 9%, compared to -95. 3% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: HIMS returned +188. 5% versus SKIN's -94. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sol-Gel Technologies Ltd.

(SLGL) is the lower-risk stock at 0. 09β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 2750% more volatile than SLGL relative to the S&P 500. On balance sheet safety, Sol-Gel Technologies Ltd. (SLGL) carries a lower debt/equity ratio of 4% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sol-Gel Technologies Ltd.

(SLGL) is pulling ahead at 68. 0% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: GoodRx Holdings, Inc. grew EPS 104. 1% year-over-year, compared to -478. 9% for Sol-Gel Technologies Ltd.. Over a 3-year CAGR, SLGL leads at 70. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -31. 6% for Sol-Gel Technologies Ltd. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GDRX leads at 11. 0% versus -39. 2% for SLGL. At the gross margin level — before operating expenses — SLGL leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, GoodRx Holdings, Inc.

(GDRX) trades at 9. 4x forward P/E versus 69. 9x for Journey Medical Corporation — 60. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 131. 8% to $11. 75.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Sol-Gel Technologies Ltd.

(SLGL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 09)). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SLGL: -48. 0%, HIMS: +188. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SLGL (Healthcare) and GDRX (Healthcare) and HIMS (Healthcare) and DERM (Healthcare) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SLGL is a small-cap high-growth stock; GDRX is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; DERM is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.